DE69429450D1 - Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung - Google Patents

Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung

Info

Publication number
DE69429450D1
DE69429450D1 DE69429450T DE69429450T DE69429450D1 DE 69429450 D1 DE69429450 D1 DE 69429450D1 DE 69429450 T DE69429450 T DE 69429450T DE 69429450 T DE69429450 T DE 69429450T DE 69429450 D1 DE69429450 D1 DE 69429450D1
Authority
DE
Germany
Prior art keywords
analog
angiotensin iii
tissue healing
wound healing
analogs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69429450T
Other languages
English (en)
Other versions
DE69429450T2 (de
Inventor
Kathleen Elizabeth Rodgers
Gere Stodder Dizerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of DE69429450D1 publication Critical patent/DE69429450D1/de
Application granted granted Critical
Publication of DE69429450T2 publication Critical patent/DE69429450T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69429450T 1993-09-24 1994-09-19 Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung Expired - Fee Related DE69429450T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12636893A 1993-09-24 1993-09-24
PCT/US1994/010503 WO1995008337A1 (en) 1993-09-24 1994-09-19 Use of angiotensin iii and analogs thereof in tissue repair

Publications (2)

Publication Number Publication Date
DE69429450D1 true DE69429450D1 (de) 2002-01-24
DE69429450T2 DE69429450T2 (de) 2002-07-25

Family

ID=22424455

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429450T Expired - Fee Related DE69429450T2 (de) 1993-09-24 1994-09-19 Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung

Country Status (13)

Country Link
US (1) US5629292A (de)
EP (1) EP0730465B1 (de)
JP (1) JPH09502977A (de)
AT (1) ATE210677T1 (de)
AU (1) AU706333B2 (de)
CA (1) CA2172493C (de)
DE (1) DE69429450T2 (de)
DK (1) DK0730465T3 (de)
ES (1) ES2168312T3 (de)
PT (1) PT730465E (de)
TW (1) TW311088B (de)
WO (1) WO1995008337A1 (de)
ZA (1) ZA947338B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
AU758319B2 (en) * 1994-11-14 2003-03-20 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
US6528483B2 (en) 1995-06-07 2003-03-04 André Beaulieu Method of producing concentrated non-buffered solutions of fibronectin
US7112320B1 (en) 1995-06-07 2006-09-26 Andre Beaulieu Solid wound healing formulations containing fibronectin
MY121607A (en) * 1995-07-10 2006-02-28 Hyundai Curitel Inc Grid moving method of object image and apparatus using the same and compaction/motion estimation method using the same and apparatus thereof
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
EP1410801B1 (de) 1997-01-28 2013-04-10 University Of Southern California Verfahren zur Förderung der hämatopoietischen Zellproliferation und Differenzierung
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
AU6650098A (en) * 1997-02-04 1998-08-25 University Of Southern California Method for accelerating healing of thermal injuries
US6197751B1 (en) 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
WO1999026644A1 (en) * 1997-11-26 1999-06-03 University Of Southern California Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
AU755225B2 (en) * 1997-12-12 2002-12-05 University Of Southern California Wound healing compositions
US6239109B1 (en) 1998-02-09 2001-05-29 University Of Southern California Method of promoting erythropoiesis
US7173011B2 (en) 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
WO1999046285A2 (en) 1998-03-11 1999-09-16 University Of Southern California Method of promoting production of living tissue equivalents
JP2002511416A (ja) * 1998-04-09 2002-04-16 ユニヴァースティ オブ サザーン カリフォルニア 感染を処置および予防するための方法
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
CA2322963C (en) 1998-05-11 2004-04-13 University Of Southern California Methods to increase white blood cell survival after chemotherapy
CA2328871C (en) 1998-07-13 2002-10-01 University Of Southern California Methods for accelerating bone and cartilage growth and repair
US6916783B2 (en) 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
AU755943B2 (en) * 1998-08-13 2003-01-02 University Of Southern California Methods to increase blood flow to ischemic tissue
ATE286511T1 (de) * 1999-02-17 2005-01-15 Pfizer Prod Inc Fusionsproteine mit trägern welche eine doppelte immunantwort induzieren
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6821953B1 (en) * 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US6747008B1 (en) 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
AU2002308522A1 (en) * 2001-05-01 2002-11-11 University Of Southern California Methods for inhibiting tumor cell proliferation
ATE522225T1 (de) * 2007-09-11 2011-09-15 Mondobiotech Lab Ag Verwendung des peptids phpfhlfvy (renin- inhibitor) in anti-angiogenischer therapie von gewissen erkrankungen
WO2009033820A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2187913B1 (de) * 2007-09-11 2012-07-11 Mondobiotech Laboratories AG Ac-RFMWMR-NH2 für die Verwendung in der Behandlung von Mycobacterium tuberculosis verwandten Erkrankungen
JP2010538989A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Ｈｂｖ感染等の治療における治療剤としてのｎｆ−カッパーｂインヒビターｓｎ５０の使用、及び必要に応じたアンギオテンシンｉｉｉの使用
WO2009033725A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of human neuropeptide as a therapeutic agent
US20090227507A1 (en) * 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
PL2376101T3 (pl) * 2008-12-29 2016-03-31 Trevena Inc Elektory beta-arestyny oraz ich kompozycje i sposoby stosowania
ES2479765T3 (es) 2011-02-02 2014-07-24 The University Of Southern California Métodos para el tratamiento de úlceras del pie diabético
CN104168907A (zh) 2012-01-31 2014-11-26 特维娜有限公司 β-抑制蛋白效应器及其组合物与使用方法
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
AU2014284496A1 (en) 2013-07-03 2016-01-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for treating cognitive dysfunction
AU2015213777A1 (en) 2014-02-07 2016-09-22 Trevena, Inc. Crystalline and amorphous forms of a beta-arrestin effector
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
WO2015179349A2 (en) 2014-05-19 2015-11-26 Trevena, Inc. Synthesis of beta-arrestin effectors
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
US9796759B2 (en) 2014-07-21 2017-10-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
MA43230A (fr) * 2015-10-14 2021-04-14 Tarix Pharmaceuticals Ltd Méthodes et compositions pour le traitement d'une épidermolyse bulleuse

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886134A (en) * 1970-03-09 1975-05-27 Morton Norwich Products Inc Analogues of angiotensin II
US5015629A (en) * 1989-06-26 1991-05-14 University Of Southern California Tissue repair

Also Published As

Publication number Publication date
ES2168312T3 (es) 2002-06-16
AU7730294A (en) 1995-04-10
CA2172493A1 (en) 1995-03-30
EP0730465A4 (de) 1997-11-12
ZA947338B (en) 1995-05-10
DK0730465T3 (da) 2002-04-08
TW311088B (de) 1997-07-21
CA2172493C (en) 2003-09-16
WO1995008337A1 (en) 1995-03-30
JPH09502977A (ja) 1997-03-25
EP0730465A1 (de) 1996-09-11
US5629292A (en) 1997-05-13
PT730465E (pt) 2002-06-28
AU706333B2 (en) 1999-06-17
DE69429450T2 (de) 2002-07-25
EP0730465B1 (de) 2001-12-12
ATE210677T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
DE69429450D1 (de) Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung
MX9703609A (es) Uso de fragmentos de angiotensina ii y analogos de la misma para la preparacion de composiciones en la preparacion de tejido.
DE69435301D1 (de) Verwendung von Angiotensin-II-Analogen zur Gewebewiederherstellung
ATE393831T1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
DE69430440T2 (de) Zusammensetzungen zur inhibition von retroviraler verbreitung, die 2',3'-dideoxy-inosin und hydroxyharnstoff enthalten
ES2155874T3 (es) Composiciones cosmeticas que contienen acido betulinico.
FI971536A0 (fi) Keratinosyytti-kasvutekijän analogeja
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
ATE435030T1 (de) Heilung von wunden oder fibrotischen krankheiten unter verwendung von wenigstens einem agens gegen einen wachstumsfaktor
DE69510775T2 (de) Methoden zur verwendung von cyclischenpolyanionischen polyderivatenzur kontrolle von hautfalten
ATE103815T1 (de) Verwendung von thrombospondin zur beschleunigung der wundheilung.
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
BR9611472A (pt) Compostos de di-terc-butilfenol contendo enxofre úteis como agentes antiinflamatórios
DK0613368T3 (da) Hudregenererende kosmetisk sammensætning
MX9709983A (es) El uso de agonistas receptores tipo 2 de angiotesina ii en la preparacion de composiciones para la preparacion de tejidos.
ES2065308T1 (es) Producto para el moldeado permanente del cabello y nuevos esteres de acido 2-hidroxi-3-mercaptopropionico reductores de la queratina capilar.
DE69931148D1 (de) Behandlung von hiv infektionen
EA199800953A1 (ru) Компонент в, используемый в качестве рубцующего агента, содержащая его фармацевтическая композиция и способ лечения
ES2165366T3 (es) Procedimientos y composiciones para inhibir la inflamacion mediada por celulas endoteliales y fibrinogeno.
UA23369A (uk) Антисептичний перев`язний матеріал

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee